Conference - New York, NY, United States
A decade after the first cancer drug targeting VEGF signaling in tumor blood vessel formation received approval by the US Food and Drug Administration (FDA), significant effort has been dedicated toward progressing the research, development, and clinical application of anti-angiogenic cancer therapies.Drawing on lessons learned from successes and failures, this conference will examine ways to improve cancer therapy by addressing urgent issues such as:
inherent /acquired resistance,
immunomodulation,
enhanced invasiveness / metastasis, and
lack of validated predictive and prognostic biomarkers.
Presentations will explore VEGF- dependent and alternative mechanisms of angiogenesis. “Point–Counterpoint” debates between leading experts will aim to resolve controversies regarding the function of vascular normalization, treatment-induced metastasis, and the validity of hypertension as a physiological biomarker.
Organization: The New York Academy of Sciences
Targeting VEGF-mediated Tumor Angiogenesis in Cancer Therapy
Thu, Jun 19, 2014 - Fri, Jun 20, 2014
The New York Academy of Sciences
7 World Trade Center, 250 Greenwich Street, 40th Fl, New York, United States
If you'd like to ask a question or post a comment about this talk please do so below.
This seminar posting is brought to you by Biotechnology Calendar, Inc. providing access to research information and research tools for nearly 20 years. Visit our Science Market Update Blog for current science funding and market information or see our schedule of upcoming science research laboratory product shows.
